William Colton

William Colton is the founder of Paldara Pharmaceuticals, a biotechnology company advancing bacteriophage-based therapeutics and localized drug delivery technologies. With a background in microbiology and molecular genetics, he focuses on developing hydrogel platforms that stabilize, transport, and precisely deliver bacteriophages to treat drug-resistant infections. Colton has experience working in public health laboratory settings and has led the development of a BSL-2 research facility dedicated to isolating and characterizing lytic bacteriophages against major ESKAPE pathogens. His work centers on translating foundational microbiology into practical clinical solutions, particularly for wound care, device-associated infections, and other high-burden bacterial diseases. Under his leadership, Paldara has established collaborations with academic medical centers and veterinary institutions to evaluate bacteriophage hydrogel applications in both preclinical and clinical settings. Colton also engages in strategic partnerships to expand the company’s platform into diagnostics and complementary therapeutic applications. His broader mission is to help address antimicrobial resistance through precision biologics and scalable delivery systems that improve safety, accessibility, and therapeutic effectiveness.